Phlow vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Phlow raised $37M Series C in July 2025 and holds $600M+ in government contracts including a $354M BARDA contract; manufactures critical active pharmaceutical ingredients and finished drug forms entirely within the U.S.
About
Phlow is a public benefit pharmaceutical company that develops and manufactures critical active pharmaceutical ingredients (APIs) and finished dosage forms entirely within the United States. Its mission is to strengthen national medicine supply chains by producing drugs domestically, reducing dependence on foreign API suppliers — primarily in China and India — that supply the majority of the U.S. medicine supply. Phlow''s manufacturing model uses continuous flow chemistry and advanced automation to produce APIs at lower cost and higher quality consistency than traditional batch manufacturing.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.